TY  - GEN
AU  - Dungan,K M
AU  - Weitgasser,R
AU  - Perez Manghi,F
AU  - Pintilei,E
AU  - Fahrbach,J L
AU  - Jiang,H H
AU  - Shell,J
AU  - Robertson,K E
TI  - A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8)
SN  - 1463-1326
PY  - 2017///0106
KW  - Aged
KW  - Diabetes Mellitus, Type 2
KW  - blood
KW  - Double-Blind Method
KW  - Drug Administration Schedule
KW  - Drug Resistance
KW  - Drug Therapy, Combination
KW  - adverse effects
KW  - Female
KW  - Glucagon-Like Peptide-1 Receptor
KW  - metabolism
KW  - Glucagon-Like Peptides
KW  - administration & dosage
KW  - Glycated Hemoglobin
KW  - analysis
KW  - Humans
KW  - Hyperglycemia
KW  - prevention & control
KW  - Hypoglycemia
KW  - chemically induced
KW  - Hypoglycemic Agents
KW  - Immunoglobulin Fc Fragments
KW  - Injections, Subcutaneous
KW  - Intention to Treat Analysis
KW  - Male
KW  - Middle Aged
KW  - Patient Dropouts
KW  - Recombinant Fusion Proteins
KW  - Sulfonylurea Compounds
KW  - Glucagon-Like Peptide-1 Receptor Agonists
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1111/dom.12634
ER  -